Remdesivir treatment for patients with moderate to severe COVID-19

Autor:	Alp, Emine, Gül, Ahmet, Tabak, Fehmi, Erdinç, Şebnem, Ünal, Serhat, Çağatay, Arif Atahan, Pullukçu, Hüsnü, Çelikbaş, Aysel, Karaali, Ridvan, Kazak, Esra, Şenoğlu, Sevtap, Yaşar, Kadriye Kart, Bozkurt, Ilkay, Sevgi, Dilek Yildiz, Eren, Esma, Dizman, Gülçin Telli, Batirel, Ayşe, Kanat, Fikret, Çelik, Ilhami, Güner, Rahmet, HASANOĞLU, İMRAN
Rok vydání:	2021
Předmět:	Adult Treatment Outcome treatment SARS-CoV-2 COVID-19 Humans remdesivir General Medicine antiviral mortality Pandemics Antiviral Agents COVID-19 Drug Treatment
Zdroj:	Turkish journal of medical sciences. 52(4)
ISSN:	1303-6165
Popis:	Background/aim: Remdesivir, which was first developed for the treatment of Ebola disease but failed to meet expectations, has become hope in the fight against the COVID-19 pandemic. This study aimed to evaluate risk factors for mortality and prognosis of adult moderate/severe COVID-19 patients treated with remdesivir, and safety and tolerability of 5 days of remdesivir treatment. Materials and methods: This multicenter prospective observational study was conducted in 14 centers in Turkey. Pregnancy or breastfeeding, multiorgan failure, or usage of vasopressors for septic shock, ALT>5 x the upper limit of the normal range, or eGRF Health Institutes of Turkey [COVID-19-PMSRMD] Health Institutes of Turkey (Project ID: COVID-19-PMSRMD).
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63ba65326c9db669751625d7aa586c07 https://pubmed.ncbi.nlm.nih.gov/36326369 Zobrazit plný text záznamu